BR9815493A - Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes - Google Patents
Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentesInfo
- Publication number
- BR9815493A BR9815493A BR9815493-1A BR9815493A BR9815493A BR 9815493 A BR9815493 A BR 9815493A BR 9815493 A BR9815493 A BR 9815493A BR 9815493 A BR9815493 A BR 9815493A
- Authority
- BR
- Brazil
- Prior art keywords
- superantigen
- conjugate
- immune modulator
- sag
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"CITóLISE DIRIGIDA DE CéLULAS-ALVO, AGENTES E COMPOSIçõES QUE CAUSAM CITóLISE, E COMPOSTOS QUE PODEM SER USADOS PARA PRODUZIR OS AGENTES". Descreve-se um método para inativar células-alvo na prevenção de células T, colocando os dois tipos de células em contato com um superantígeno (SAG), na presença de um modulador imunológico, distinguindo-se pelo fato de que pelo menos um entre o superantígeno e o modulador imunológico está na forma de um conjugado entre um superantígeno "livre" (Sag) e um grupamento assestante de alvos do conjugado para assestar em células. Descreve-se também um conjugado de superantígeno que obedece à fórmula (I): (T) x (Sag) y (IM) z; a) T é um grupamento assestante de alvos, Sag corresponde a um superantígeno livre, IM é um modulador imunológico que não é um superantígeno, e T, Sag e IM estão ligados entre si por intermédio de ligantes orgânicos B; b) x, y e z são números inteiros que são tipicamente selecionados entre 0 a 10, e representam o número de grupamentos T, Sag e Im, respectivamente, em uma dada molécula de conjugado, com a ressalva de que y > 0 e também um ou ambos entre x e z > 0. O conjugado de superantígeno é, de preferência, uma proteína de fusão tripla. Descreve-se também um modulador imunológico assestado, distinguido pelo fato de que ele é um conjugado entre um grupamento assestante de alvos (T" ') e um modulador imunológico modificado (IM" '). O conjugado obedece a uma fórmula análoga à fórmula (I), exceto pela presença imperativa do modulador imunológico modificado. Um grupamento de superantígeno pode estar presente. Descreve-se também uma molécula de Dna que codifica um superantígeno e um modulador imunológico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5321197P | 1997-07-21 | 1997-07-21 | |
SE9704170A SE9704170D0 (sv) | 1997-11-14 | 1997-11-14 | Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents |
PCT/EP1998/004219 WO1999004820A2 (en) | 1997-07-21 | 1998-07-02 | Cytolysis of target cells by superantigen conjugates inducing t-cell activation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9815493A true BR9815493A (pt) | 2000-10-31 |
Family
ID=26663128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9815493-1A BR9815493A (pt) | 1997-07-21 | 1998-07-02 | Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes |
Country Status (19)
Country | Link |
---|---|
US (2) | US6962694B1 (pt) |
EP (1) | EP0998305B1 (pt) |
JP (1) | JP2001510687A (pt) |
KR (1) | KR20010022075A (pt) |
CN (1) | CN1275085A (pt) |
AR (1) | AR013230A1 (pt) |
AT (1) | ATE361102T1 (pt) |
AU (1) | AU748097B2 (pt) |
BR (1) | BR9815493A (pt) |
CA (1) | CA2296798A1 (pt) |
DE (1) | DE69837706T2 (pt) |
EA (1) | EA002688B1 (pt) |
ES (1) | ES2284209T3 (pt) |
ID (1) | ID24097A (pt) |
IL (1) | IL133883A0 (pt) |
NO (1) | NO20000265L (pt) |
NZ (1) | NZ502745A (pt) |
PL (1) | PL338338A1 (pt) |
WO (1) | WO1999004820A2 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000002050A1 (en) * | 1998-07-07 | 2000-01-13 | Department Of Radiation Oncology, University Of Washington | Trifunctional reagent for conjugation to a biomolecule |
US20010023288A1 (en) | 1999-07-07 | 2001-09-20 | Wilbur D. Scott | Trifunctional reagent for conjugation to a biomolecule |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
US7885841B2 (en) * | 2006-01-05 | 2011-02-08 | Oracle International Corporation | Audit planning |
DE102007004855B4 (de) * | 2007-01-31 | 2014-03-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Vorrichtung und Verfahren zur Deposition von biologischem Material in einem Zielsubstrat |
EP2839839B1 (en) | 2007-02-28 | 2018-01-17 | Yeda Research And Development Company Limited | Nuclear targeting sequences |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
ES2758884T3 (es) * | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9695402B2 (en) | 2013-09-17 | 2017-07-04 | Yeda Research And Development Co. Ltd. | ERK-derived peptides and uses thereof |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
AU2017206656B2 (en) | 2016-01-10 | 2024-02-01 | Neotx Therapeutics Ltd. | Immunopotentiator enhanced superantigen mediated cancer immunotherapy |
WO2018067461A1 (en) * | 2016-10-05 | 2018-04-12 | The Regents Of The University Of California | Viral disk assemblies and methods of use thereof |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
EP3969043A1 (en) | 2019-05-15 | 2022-03-23 | Neotx Therapeutics Ltd. | Cancer treatment |
AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993024136A1 (en) * | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
US5545716A (en) * | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
IL113484A0 (en) * | 1994-04-28 | 1995-07-31 | Immunex Corp | Viral proteins pharmaceutical compositions containing them their preparation and use |
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5716623A (en) * | 1994-12-07 | 1998-02-10 | Immunex Corporation | Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules |
US5705151A (en) * | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
WO1998026747A2 (en) * | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
US6075119A (en) * | 1997-04-07 | 2000-06-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
-
1998
- 1998-07-02 NZ NZ502745A patent/NZ502745A/xx not_active IP Right Cessation
- 1998-07-02 EP EP98935025A patent/EP0998305B1/en not_active Expired - Lifetime
- 1998-07-02 CA CA002296798A patent/CA2296798A1/en not_active Abandoned
- 1998-07-02 DE DE69837706T patent/DE69837706T2/de not_active Expired - Lifetime
- 1998-07-02 AU AU84415/98A patent/AU748097B2/en not_active Ceased
- 1998-07-02 ID IDW20000328A patent/ID24097A/id unknown
- 1998-07-02 AT AT98935025T patent/ATE361102T1/de not_active IP Right Cessation
- 1998-07-02 CN CN98808475A patent/CN1275085A/zh active Pending
- 1998-07-02 PL PL98338338A patent/PL338338A1/xx unknown
- 1998-07-02 IL IL13388398A patent/IL133883A0/xx unknown
- 1998-07-02 KR KR1020007000644A patent/KR20010022075A/ko not_active Application Discontinuation
- 1998-07-02 BR BR9815493-1A patent/BR9815493A/pt not_active IP Right Cessation
- 1998-07-02 ES ES98935025T patent/ES2284209T3/es not_active Expired - Lifetime
- 1998-07-02 EA EA200000144A patent/EA002688B1/ru not_active IP Right Cessation
- 1998-07-02 JP JP2000503871A patent/JP2001510687A/ja active Pending
- 1998-07-02 WO PCT/EP1998/004219 patent/WO1999004820A2/en active IP Right Grant
- 1998-07-17 AR ARP980103502A patent/AR013230A1/es not_active Application Discontinuation
- 1998-07-21 US US09/463,470 patent/US6962694B1/en not_active Expired - Fee Related
-
2000
- 2000-01-19 NO NO20000265A patent/NO20000265L/no not_active Application Discontinuation
-
2004
- 2004-12-27 US US11/023,086 patent/US20050226885A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69837706D1 (de) | 2007-06-14 |
WO1999004820A2 (en) | 1999-02-04 |
KR20010022075A (ko) | 2001-03-15 |
EA200000144A1 (ru) | 2000-08-28 |
NO20000265L (no) | 2000-03-15 |
NO20000265D0 (no) | 2000-01-19 |
ES2284209T3 (es) | 2007-11-01 |
AU8441598A (en) | 1999-02-16 |
CA2296798A1 (en) | 1999-02-04 |
ATE361102T1 (de) | 2007-05-15 |
EA002688B1 (ru) | 2002-08-29 |
AR013230A1 (es) | 2000-12-13 |
DE69837706T2 (de) | 2008-01-10 |
AU748097B2 (en) | 2002-05-30 |
NZ502745A (en) | 2003-02-28 |
IL133883A0 (en) | 2001-04-30 |
EP0998305B1 (en) | 2007-05-02 |
US6962694B1 (en) | 2005-11-08 |
CN1275085A (zh) | 2000-11-29 |
JP2001510687A (ja) | 2001-08-07 |
WO1999004820A3 (en) | 1999-08-12 |
ID24097A (id) | 2000-07-06 |
EP0998305A2 (en) | 2000-05-10 |
US20050226885A1 (en) | 2005-10-13 |
PL338338A1 (en) | 2000-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9815493A (pt) | Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes | |
Brown et al. | The stimulation of pp60v-src kinase activity by vanadate in intact cells accompanies a new phosphorylation state of the enzyme. | |
Tong et al. | Ligand interactions of the cation-independent mannose 6-phosphate receptor: the stoichiometry of mannose 6-phosphate binding | |
BR0213303A (pt) | Proteìnas de ligação de alvejamento direto | |
DE69800640D1 (en) | Pegylationsverfahren | |
ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
NO995349L (no) | Multivalent vaksinasjonssammensetning med blandet baerer | |
GR3026658T3 (en) | Hydrazino-type radionuclide chelators having an n 3?s configuration | |
ES2180938T3 (es) | Donadores de oxido nitrico capaces de reducir la toxicidad de los farmacos. | |
BR0108713A (pt) | Expressão hìbrida de proteìnas de neisseria | |
BRPI0511835A (pt) | enzima lipolìtica e seus usos na indústria alimentìcia | |
AR020054A1 (es) | COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS | |
BR0114199A (pt) | Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas | |
SE8702550D0 (sv) | Cysteinproteashemmare | |
DK0998501T3 (da) | Kationiske polymerer, komplekser, som associerer de kationiske polymerer og terapeutisk aktive substanser, der omfatter mindst én negativ ladning, især nukleinsyrer, og anvendelse i genterapi | |
DE60104421D1 (de) | Prochelators von radiometall markierten molekülen | |
CY1106181T1 (el) | Φαρμακευτικος σχηματισμος ο οποιος πepιλαμβανει γλυκινη σαν ενα σταθepοποιητη | |
AR020326A1 (es) | Proteina homologa a poli (adp-ribosa) polimerasa (parp), acido nucleico, vector recombinante, mamifero o celula eucariota parp-deficiente, metodo dedeteccion in vitro para inhibidores parp, composicion farmaceutica | |
Hunter et al. | Allelic variants in the amino-acid sequence of the α chain of rabbit haemoglobin | |
DE69132044D1 (de) | Markierte, modifizierte Oligonokleotiden | |
DE60044433D1 (de) | Transportproteine fuer organische anionen | |
NO20011817L (no) | Ionebytte-tumormålsöking (IETT) | |
BR9710849A (pt) | Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina. | |
TR200001724T2 (tr) | 5-HT1F Agonistleri | |
NO995858D0 (no) | Ny klasse kationiske nukleinsyre-overföringsmidler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7O, 8O , E 9O ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/47 (2006.01), A61K 47/64 (2017.0 |